These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 6011791)
21. Pharmacological properties of a new potential neuroleptic drug oxyprothepin. II. Influence on behaviour in rats. Kazdová E; Metysová J; Dlabac A Act Nerv Super (Praha); 1971; 13(3):186-7. PubMed ID: 5113831 [No Abstract] [Full Text] [Related]
22. Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect? Costall B; Naylor RJ Psychopharmacologia; 1973; 32(2):161-70. PubMed ID: 4796282 [No Abstract] [Full Text] [Related]
24. Pharmacological studies on the brain mechanisms underlying two forms of behavioral excitation: stereotyped hyperactivity and "rage". Randrup A; Munkvad I Ann N Y Acad Sci; 1969 Jul; 159(3):928-38. PubMed ID: 4902868 [No Abstract] [Full Text] [Related]
26. Definition and classification of neuroleptics. Arnold OH; Collard J; Deniker P; Ginestet D; Hippius H; Itil TM; Labhardt F; Leeds AA; Montanini R; Morozov G; Simon P; Villeneuve A Mod Probl Pharmacopsychiatry; 1970; 5():141-7. PubMed ID: 5527163 [No Abstract] [Full Text] [Related]
27. Effect of intraventricularly administered prostaglandin E1 on the electrical activity of cerebral cortex and behavior in the unanesthetized monkey. Desiraju T Prostaglandins; 1973 Jun; 3(6):859-70. PubMed ID: 4199677 [No Abstract] [Full Text] [Related]
28. Effects of chronic administration of neuroleptics: dyskinesias in monkeys. Paulson G Pharmacol Ther B; 1976; 2(1):167-71. PubMed ID: 4829 [No Abstract] [Full Text] [Related]
29. Pharmacological profile of a new psychotherapeutic agent: 4-p-fluorophenyl-5-N(N'-o-methoxyphenyl)piperazinoethyl-4-oxazolin-2-one (LR 511). Fregnan GB; Vidali M Pharmacology; 1977; 15(6):485-502. PubMed ID: 563604 [No Abstract] [Full Text] [Related]
30. [Study of extrapyramidal manifestations induced by neuroleptics]. Bordeleau JM; Tétreault L Rev Can Biol; 1972; 31():Suppl:247-53. PubMed ID: 4403291 [No Abstract] [Full Text] [Related]
31. Behavioural effects in rats of morphine and amphetamine and of a combination of the two drugs. Fog R Psychopharmacologia; 1970; 16(4):305-12. PubMed ID: 5461437 [No Abstract] [Full Text] [Related]
32. Long-term trial of fluphenazine decanoate and flupenthixol decanoate for cataleptic activity and effect on motor activity in rats. Chandra O; Bernard J; Matussek N Arzneimittelforschung; 1974 Nov; 24(11):1821-4. PubMed ID: 4480057 [No Abstract] [Full Text] [Related]
33. Effects of phenothiazine derivatives on the sleep-wakefulness cycle in growing kittens. Shimizu A; Himwich HE Folia Psychiatr Neurol Jpn; 1968; 22(4):297-305. PubMed ID: 5756541 [No Abstract] [Full Text] [Related]
34. The antisialogogue effect of phenothiazine derivatives: comparison of pecazine, perphenazine, fluphenazine, thiopropazate, pipamazine and triflupromazine. DOBKIN AB; PURKIN N Br J Anaesth; 1960 Feb; 32():57-9. PubMed ID: 13817061 [No Abstract] [Full Text] [Related]
37. A rational framework for the development, evaluation, and use of psychoactive drugs. Irwin S Am J Psychiatry; 1968 Feb; 124(8):Suppl:1-19. PubMed ID: 4865729 [No Abstract] [Full Text] [Related]
38. Spiranes. XII. Azaspiranylalkylphenothiazines. Grogan CH; Kelly R; Rice LM J Med Chem; 1966 Sep; 9(5):654-6. PubMed ID: 5969032 [No Abstract] [Full Text] [Related]